Navigation Links
Cardiac Science Expands Device Connectivity Solutions
Date:7/21/2011

BOTHELL, Wash., July 21, 2011 /PRNewswire/ -- Cardiac Science Corporation, a global leader in automated external defibrillators (AEDs) and diagnostic cardiac monitoring devices that connect to electronic medical records (EMRs) and hospital information systems, announced today the new capability of direct communication between the Cardiac Science HeartCentrix® connectivity solution and the GE Healthcare Centricity® EMR system.

(Logo: http://photos.prnewswire.com/prnh/20080306/AQTH510LOGO)

"Our customers want to connect cardiac monitoring devices with leading EMRs," said Dave Marver, CEO of Cardiac Science. "With the addition of GE Centricity, we now offer integration solutions with each of the top ten EMR companies."

This integration solution will provide thousands of physicians with the ability to connect Cardiac Science devices to GE Centricity EMR. The connectivity solution supports both purpose-built and PC-based cardiology devices, including the new Cardiac Science CareCenter MD™ diagnostic workstation. HeartCentrix can connect with new and existing Centricity systems, including versions 9.2 and higher.

The Cardiac Science HeartCentrix connectivity solution gives physician offices and cardiology practices the ability to send data from their diagnostic and monitoring devices into EMR systems.  By eliminating manual transcription processes, HeartCentrix helps streamline workflow and create efficiencies.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators ('/>"/>

SOURCE Cardiac Science Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
2. Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED
3. Reportlinker Adds US Cardiac Assist Devices -- Market Trend Till 2016
4. Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S.
5. Reportlinker Adds European Markets for Cardiac Surgery Devices
6. SCAA Puts the AED in CPR/AED Week to Make Communities Safer, Better Equipped to Respond to Cardiac Arrest
7. Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death
8. Cardiac Network Announces Reverse Stock Split
9. Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011
10. NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capitals Bright Lights Conference in New York City on May 10, 2011
11. Reportlinker Adds Cardiac Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecast to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)...  Indianapolis interventional medical device maker NICO ... 3D visualization leader Synaptive Medical announced ... Meeting that they have joined forces to integrate ... is the first of its kind and will ... NICO,s BrainPath® interventional access technology and Synaptive,s BrightMatter™ ...
(Date:10/20/2014)... --  BioNano Genomics announced today achievement of a major ... data at 30X depth, sufficient for a genome map, in ... established and demonstrated for the IrysChip TM V2, the ... and will be rolled out to BioNano,s collaborators and customers ... advancement at the American Society for Human Genetics (ASHG) ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused ... Food and Drug Administration ("FDA") accepted the Company,s ... of AR-12, a potentially first-in-class, orally available, PDK1 ... the endoplasmic reticulum stress pathway. Acceptance of ...
... ValueOptions(R), Inc., the nation,s largest ... support for the use of The Joint Commission,s ... basis for the recently completed pilot program was ... to help patients receive the most appropriate and ...
Cached Medicine Technology:FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 2FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway 3ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services 2
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... VEENENDAAL, the Netherlands, September 3 , ... for the First Half Year , ... results over the first half year of 2009. Despite challenging,global ... Net sales amounted to EUR 51.2 ...
... , CORAL GABLES, Fla., Sept. 2 Catalyst ... from The NASDAQ Stock Market to transfer the listing of its common ... transfer will be effective at the opening of the market on September ... no impact on the ability of investors to trade the stock. , ...
... , , WASHINGTON, Sept. 2 ... today to President Obama inviting him to address a Joint Session of Congress on ... the text of the letter to the President: , , ... House , Washington, D.C. 20500 , , Dear Mr. President: , ...
... , , ATLANTA, Sept. 2 ... GTIV ), a leading provider of comprehensive home health services, announced ... Inc. (d/b/a Magna Home Health), a part of the Rush Health ... was funded from Gentiva,s existing cash reserves. , , ...
... , , WASHINGTON, Sept. ... President, Campaign for Tobacco-Free Kids: , , (Logo: ... have taken decisive action to protect the state,s kids and taxpayers from ... by $1 to $3.00 per pack, making it the second highest state ...
... basal cell carcinomas responded to treatment , WEDNESDAY, Sept. ... off the so-called "Hedgehog" pathway beat back tumors in more ... type of skin cancer. , The drug also helped a ... brain cancer in children. , "We were both pleased and ...
Cached Medicine News:Health News:Nucletron Increases Full Year Outlook After Strong First Half 2009 2Health News:Catalyst Pharmaceutical Partners To Transfer To NASDAQ Capital Market 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 2Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 3Health News:New Compound Shrinks Skin Cancers 2Health News:New Compound Shrinks Skin Cancers 3Health News:New Compound Shrinks Skin Cancers 4
... Open heart surgery is no longer ... septal defects in young children and in ... care providers are seeking non-surgical options to ... Occluder is a permanently implanted prosthesis and ...
... Network (NLTN) is a training system sponsored ... (APHL) and the Centers for Disease Control ... in a variety of formats and offers ... Library. Log on to www.nltn.org for a ...
... Testing and Quality Assurance (for Waived and ... POLs, clinics and small hospitals maintain laboratory ... of patient lab results and assist labs ... opportunity to earn 12 P.A.C.E. Contact hours ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
Medicine Products: